A Phase II Study to Evaluate the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic LPSCC/HPSCC

NCT06793761 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

260

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer

Interventions

DRUG: Pembrolizumab
DRUG: Cisplatin
DRUG: Nab-paclitaxel

Sponsor

Beijing Tongren Hospital